Pengaruh Pemberian Rejimen Antiretroviral Yang Mengandung Zidovudine Atau Tenofovir Terhadap Kadar Lipid Pada Orang Dengan Hiv Aids (Odha)

53

Lampiran 1: Surat Persetujuan Komite Etik

Universitas Sumatera Utara

54

Lampiran 2

LEMBAR PENJELASAN KEPADA CALON SUBJEK PENELITIAN

Selamat pagi/siang Bapak/Ibu/Saudara/I, pada hari ini saya, dr.Eva
Roswati, peserta Pendidikan Pasca Sarjana Ilmu Penyakit Dalam / Magister
Klinik FK USU Medan akan melakukan penelitian yang berjudul ” Pengaruh
pemberian rejimen antiretroviral (ARV) yang mengandung Zidovudine atau
Tenofovir terhadap kadar lipid pada orang dengan HIV/AIDS (ODHA)”.
Penelitian ini bertujuan melihat pengaruh pemberian obat antiretroviral yang
mengandung Zidovudine atau Tenofovir selama 6 bulan terhadap kadar lipid
serum. Sebagai informasi, yang dikatakan sebagai penderita HIV-AIDS adalah
subyek yang terinfeksi virus HIV yang memerlukan terapi obat anti virus untuk

mengobati penyakitnya. Diperlukan kepatuhan untuk meminum obat anti virus
tersebut agar keberhasilan terapi dapat tercapai. Namun demikian, pemberian obat
anti virus juga mempengaruhi kadar lipid. Untuk itu peneliti ingin mengetahui
apakah ada hubungan antara obat tersebut dengan kadar lipid .
Bapak/Ibu/Saudara/Saudari yang bersedia mengikuti penelitian ini
nantinya akan diminta mengisi surat persetujuan ikut dalam penelitian, mengikuti
wawancara untuk mencari adanya hal-hal yang dapat mengganggu penelitian.
Untuk penelitian ini akan dilakukan pengambilan darah pada daerah lipatan siku
Bapak/Ibu/Saudara/i sebanyak ±15 cc (1 sendok makan) oleh ahlinya untuk
pemeriksaan darah rutin, fungsi hati, fungsi ginjal, kadar glukosa darah, kadar
lipid setelah Bapak/Ibu berpuasa 12-16jam semalam sebelum pengambilan darah.
Di akhir minggu ke 24 nantinya akan dilakukan pemeriksaan ulangan untuk
menilai efek apakah terdapat pengaruh dalam hal ini: kadar lipid dari pemberian
obat antiretroviral yang telah Bapak/Ibu/Saudara/Saudari minum. Segala biaya
pemeriksaan laboratorium menjadi tanggung jawab peneliti. Bila masih terdapat
pertanyaan atau keluhan sewaktu penelitian ini berjalan, maka
Bapak/Ibu/Saudara/Saudari dapat menghubungi saya pada:
Nama
: dr.Eva Roswati
Alamat

: Jl. Gajah Mada No. 14 Medan
Telepon
: 08116074047
Atas Perhatian Bapak/Ibu, Saudara/i saya ucapkan terima kasih.
Peneliti,

(dr.Eva Roswati)

Universitas Sumatera Utara

55

Lampiran 3

LEMBAR PERSETUJUAN SETELAH PENJELASAN
(INFORMED CONSENT)

Saya yang bertandatangan di bawah ini:
Nama


: ............................................................................

Alamat

: ............................................................................

Umur

: ............................................................................

Jenis Kelamin

: Laki-laki/ Perempuan

No Telp

: ............................................................................

Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan
prosedur penelitian ini, saya menyatakan bersedia ikut serta dalam penelitian

tentang

“Pengaruh

pemberian

rejimen

antiretroviral

(ARV)

yang

mengandung Zidovudine atau Tenofovir terhadap kadar lipid pada orang
dengan HIV/AIDS (ODHA)”. Apabila sewaktu-waktu saya mengudurkan diri
dari penelitian ini, kepada saya tidak dituntut apapun.
Demikian surat persetujuan bersedia ikut dalam penelitian ini saya buat untuk
dapat dipergunakan seperlunya.
Medan, ……………..


Saksi

(_________________ )

Yang memberi pernyataan

(_________________ )

Universitas Sumatera Utara

56

Lampiran 4

KERTAS KERJA PROFIL PESERTA PENELITIAN
I. IDENTITAS PRIBADI.
Nama
Umur
Jenis Kelamin

Pendidikan Terakhir
Pekerjaan
Alamat
Faktor resiko
Nomor Rekam Medis

: .............................
: .............................
: Laki-laki/Perempuan.
: .............................
: .............................
: .............................
: ……………………
: ……………………

II.PEMERIKSAAN FISIK
Parameter Antropometri
Berat Badan (kg)
Tinggi Badan (m2)
Indeks Massa Tubuh (kg/m2 )


Hasil

III.PEMERIKSAAN LABORATORIUM
Parameter Metabolik
Hemoglobin
Hematokrit
Trombosit
Lekosit
Hitung jenis lekosit
Ureum
Kreatinin
SGOT
SGPT
Kadar Glukosa Darah
CD4
Kolesterol total
Trigliserid
HDL kolesterol
LDL kolesterol

EKG

Hasil

Universitas Sumatera Utara

57

Lampiran 5

DAFTAR RIWAYAT HIDUP

I.

II.

Identitas Pribadi
Nama

: dr. Eva Roswati


Tempat/Tgl Lahir

: Jakarta/ 24 November 1977

Suku/Bangsa

: Batak/ Indonesia

Agama

: Kristen Protestan

Status

: Menikah

Alamat

: Jl. Gajah Mada Gg. Sersan No. 14 Medan


Telpon Selluler

: 08116074047

Keluarga
Nama suami

: Ir. Sarma Aries H. Lumban Gaol

Anak

: 1. Josh Richard Lumban Gaol
2. Daireann Ersah Lumban Gaol

III.

IV.

Pendidikan

SDN 09 Pagi Ragunan, Jakarta

Tamat Tahun 1989

SMPN 175 Jagakarsa, Jakarta

Tamat Tahun 1992

SMAN 28 Pasar Minggu, Jakarta

Tamat Tahun 1995

Fakultas Kedokteran Universitas Sumatera Utara

Tamat Tahun 2001

PPDS Ilmu Penyakit Dalam FK USU

2010 - sekarang

Riwayat Pekerjaan
Dokter ICU RSPAD Gatot Soebroto, Jakarta
Dokter PTT RSU Dr. Hadrianus Sinaga Pangururan, Samosir
Dokter UGD RSPAD Gatot Soebroto, Jakarta
Staf Pusat Penanggulangan Krisis Kemenkes RI, Jakarta

Universitas Sumatera Utara

58

V.

Perkumpulan Profesi
Anggota IDI Cabang Medan
Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI)

VI.

Tulisan Ilmiah
1. Diagnosis dan Tatalaksana Koagulasi Intravaskular Diseminata pada
Sepsis
2. Insufisiensi adrenal pada pasien dengan penyakit kritis
3. Dispepsia Tukak : Diagnosis dan Manajemen
4. Makna Klinis Kadar Troponin T pada penyakit jantung
5. Pemakaian Obat-obat sistemik pada penyakit ginjal kronik
6. Acute Respiratory Distress Syndrome
7. Manifestasi Klinis dari Alergi Makanan
8. Penggunaan sistem skor sebagai panduan thromboprofilaksis pada
populasi ibu hamil dengan resiko tinggi
9. Bagaimana manifestasi jiwa yang sehat

VII. Publikasi Ilmiah
1. Sindroma

Cushing

Iatrogenik

dan

Dermatitis

Eksfoliativa

Generalisata: Laporan Kasus. 4 th Endocrinology & Diabetes Forum
Of Sumatera Region. Banda Aceh, 2012.
2. Pengalaman Menangani Kasus Serial Malaria Berat di RS H.Adam
Malik Tahun 2011 – Mei 2012 : Laporan Kasus. PETRI, Banda Aceh,
2012

VIII. Partisipasi Dalam Kegiatan Ilmiah
1. Peserta Simposium “The New Option of Insulin Resistance Treatment
in Type 2 Diabetes”, Hermes Palace Hotel Medan, 20 November 2011

2. Panitia “Current Challenges Management on Infections”. PETRISUMUT. Hotel Danau Toba International. Medan 26-27 November
2011.

Universitas Sumatera Utara

59

3. Peserta Simposium “Rationale Strategy in the Management of
Pancreatic B Dysfunction and Role of Oral Incretin Based Therapy in
Type 2 Diabetes Mellitus”, Hotel J.W. Marriott Medan, 29 Januari
2012.
4. Peserta Simposium The New Direction in The Treatment of Type 2
Diabetes Melitus “A New Novel DPP-4 Inhibitor For T2DM
Treatment”, Hotel J.W. Marriott Medan, 1 April 2012

5. Peserta Roadshow Hipertensi PB PAPDI “The Next Big Target in
Hypertension: Controlling All Key BP Parameters”, Hotel J.W.
Marriott Medan, 28 April 2012
6. Peserta Seminar dan Lokakarya Sehari: Comperhensive Management
of Nausea-Vomiting and Acid Related Diseases, 5 Mei 2012.

7. Peserta Simposium “Diagnostik dan Manajemen Terkini di Bidang
Ilmu Penyakit Dalam, Fokus pada Infeksi”. PIT Penyakit Dalam XIII
& Infection Update V. Hotel Danau Toba Internasional. Medan, 9-10
Juni 2012.
8. Peserta Simposium Kongres Nasional XV Perhimpunan Dokter
Spesialis Penyakit Dalam Indonesia (KOPAPDI XV), Hotel J.W.
Marriott dan Hotel Grand Aston Medan, 12-15 Desember 2012
9. Peserta Workshop USG PAD, FEDS V, Hotel Grand Aston Medan,
Februari 2013
10. Panitia Workshop & Simposium “Meningkatkan Kemampuan Dalam
Menghadapi Penyakit Infeksi Masa Kini” Infection Update VI. PETRI
SUMUT. Hotel Danau Toba Internasional. Medan 6-7 September
2013.
11. Peserta Workshop “USG”. Pertemuan Ilmiah Tahunan Ilmu Penyakit
Dalam XIV & Gastroentero-Hepatologi Update XI. Hotel Tiara
Convention Center. Medan 12-14 September 2013.
12. Peserta Workshop & Simposium Medan Chest and Clinical
Immunology (MCCI). Hotel Tiara Convention Center. Medan, 5-7

Desember 2013.

Universitas Sumatera Utara

60

Lampiran 6
HASIL STATISTIK

Karakteristik Dasar Subjek Penelitian
Crosstab Jenis kelamin
rejimen
Naive
jk

Laki-laki

Count

Total

Zidovudine

Tenofovir

11

12

14

37

12,3

12,3

12,3

37,0

% within jk

29,7%

32,4%

37,8%

100,0%

% within rejimen

52,4%

57,1%

66,7%

58,7%

Count

10

9

7

26

Expected Count

8,7

8,7

8,7

26,0

% within jk

38,5%

34,6%

26,9%

100,0%

% within rejimen

47,6%

42,9%

33,3%

41,3%

21

21

21

63

21,0

21,0

21,0

63,0

33,3%

33,3%

33,3%

100,0%

100,0%

100,0%

100,0%

100,0%

Expected Count

Perempuan

Total

Count
Expected Count
% within jk
% within rejimen
Chi-Square Tests

Asymp. Sig. (2Value

df

sided)

a

2

,632

Likelihood Ratio

,926

2

,629

Linear-by-Linear Association

,870

1

,351

Pearson Chi-Square

N of Valid Cases

,917

63

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 8,67.

Universitas Sumatera Utara

61

Crosstab Pendidikan
rejimen
Naive
pendidikan

SD

Count

1

7

2,3

2,3

2,3

7,0

14,3%

71,4%

14,3%

100,0%

4,8%

23,8%

4,8%

11,1%

4

1

1

6

2,0

2,0

2,0

6,0

% within pendidikan

66,7%

16,7%

16,7%

100,0%

% within rejimen

19,0%

4,8%

4,8%

9,5%

11

8

11

30

10,0

10,0

10,0

30,0

% within pendidikan

36,7%

26,7%

36,7%

100,0%

% within rejimen

52,4%

38,1%

52,4%

47,6%

2

1

0

3

1,0

1,0

1,0

3,0

66,7%

33,3%

0,0%

100,0%

9,5%

4,8%

0,0%

4,8%

3

6

8

17

5,7

5,7

5,7

17,0

% within pendidikan

17,6%

35,3%

47,1%

100,0%

% within rejimen

14,3%

28,6%

38,1%

27,0%

21

21

21

63

21,0

21,0

21,0

63,0

33,3%

33,3%

33,3%

100,0%

100,0%

100,0%

100,0%

100,0%

% within rejimen
Count
Expected Count

Count
Expected Count

AKADEMI

Count
Expected Count
% within pendidikan
% within rejimen

SARJANA

Count
Expected Count

Total

Total

5

% within pendidikan

SMA

Tenofovir

1

Expected Count

SMP

Zidovudine

Count
Expected Count
% within pendidikan
% within rejimen

Chi-Square Tests
Asymp. Sig. (2Value
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

df

sided)

12,407a

8

,134

12,788

8

,119

1,779

1

,182

63

a. 9 cells (60,0%) have expected count less than 5. The minimum
expected count is 1,00.

Universitas Sumatera Utara

62

Crosstab Pekerjaan
rejimen
Naive
pekerjaan

swasta

Count

9

24

8,0

8,0

8,0

24,0

% within pekerjaan

29,2%

33,3%

37,5%

100,0%

% within rejimen

33,3%

38,1%

42,9%

38,1%

5

2

2

9

3,0

3,0

3,0

9,0

% within pekerjaan

55,6%

22,2%

22,2%

100,0%

% within rejimen

23,8%

9,5%

9,5%

14,3%

2

4

3

9

3,0

3,0

3,0

9,0

22,2%

44,4%

33,3%

100,0%

9,5%

19,0%

14,3%

14,3%

2

0

1

3

1,0

1,0

1,0

3,0

66,7%

0,0%

33,3%

100,0%

9,5%

0,0%

4,8%

4,8%

3

1

1

5

1,7

1,7

1,7

5,0

% within pekerjaan

60,0%

20,0%

20,0%

100,0%

% within rejimen

14,3%

4,8%

4,8%

7,9%

2

4

5

11

3,7

3,7

3,7

11,0

18,2%

36,4%

45,5%

100,0%

9,5%

19,0%

23,8%

17,5%

Count

0

1

0

1

Expected Count

,3

,3

,3

1,0

% within pekerjaan

0,0%

100,0%

0,0%

100,0%

% within rejimen

0,0%

4,8%

0,0%

1,6%

Count

0

1

0

1

Expected Count

,3

,3

,3

1,0

% within pekerjaan

0,0%

100,0%

0,0%

100,0%

% within rejimen

0,0%

4,8%

0,0%

1,6%

21

21

21

63

21,0

21,0

21,0

63,0

Count

Count
Expected Count
% within pekerjaan
% within rejimen

Petani

Count
Expected Count
% within pekerjaan
% within rejimen

PNS

Count
Expected Count

Swasta

Count
Expected Count
% within pekerjaan
% within rejimen

Supir

Mahasiswa

Total

Total

8

Expected Count

IRT

Tenofovir

7

Expected Count

Tidak Bekerja

Zidovudine

Count
Expected Count

Universitas Sumatera Utara

63

% within pekerjaan
% within rejimen

33,3%

33,3%

33,3%

100,0%

100,0%

100,0%

100,0%

100,0%

Chi-Square Tests
Asymp. Sig. (2Value
Pearson Chi-Square

df
14

,623

12,818

14

,541

,050

1

,824

11,789

Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

sided)

a

63

a. 21 cells (87,5%) have expected count less than 5. The minimum
expected count is ,33.

Crosstab Faktor Risiko
rejimen
Naive
FR

Heteroseksual

Count

Transfusi

15

49

16,3

16,3

16,3

49,0

% within FR

34,7%

34,7%

30,6%

100,0%

% within rejimen

81,0%

81,0%

71,4%

77,8%

0

2

5

7

2,3

2,3

2,3

7,0

% within FR

0,0%

28,6%

71,4%

100,0%

% within rejimen

0,0%

9,5%

23,8%

11,1%

Count

0

1

0

1

Expected Count

,3

,3

,3

1,0

% within FR

0,0%

100,0%

0,0%

100,0%

% within rejimen

0,0%

4,8%

0,0%

1,6%

Count

1

0

0

1

Expected Count

,3

,3

,3

1,0

100,0%

0,0%

0,0%

100,0%

4,8%

0,0%

0,0%

1,6%

2

0

1

3

1,0

1,0

1,0

3,0

66,7%

0,0%

33,3%

100,0%

9,5%

0,0%

4,8%

4,8%

1

1

0

2

Count

% within FR
% within rejimen
IDU

Count
Expected Count
% within FR
% within rejimen

Hetero Tatto

Total

17

Expected Count

Bisexual

Tenofovir

17

Expected Count

Homoseksual

Zidovudine

Count

Universitas Sumatera Utara

64

Expected Count
% within FR

,7

,7

,7

2,0

50,0%

50,0%

0,0%

100,0%

4,8%

4,8%

0,0%

3,2%

21

21

21

63

21,0

21,0

21,0

63,0

33,3%

33,3%

33,3%

100,0%

100,0%

100,0%

100,0%

100,0%

% within rejimen
Total

Count
Expected Count
% within FR
% within rejimen
Chi-Square Tests

Asymp. Sig. (2Value
Pearson Chi-Square

df
10

,247

15,959

10

,101

,726

1

,394

12,592

Likelihood Ratio

sided)

a

Linear-by-Linear Association
N of Valid Cases

63

a. 15 cells (83,3%) have expected count less than 5. The minimum
expected count is ,33.
Descriptives Usia, IMT dan CD4
rejimen
usia

Naive

Statistic
Mean

35,2381

95% Confidence Interval for

Lower Bound

31,3786

Mean

Upper Bound

39,0976

5% Trimmed Mean

34,9259

Median

33,0000

Variance

1,85023

71,890

Std. Deviation

Zidovudine

Std. Error

8,47883

Minimum

22,00

Maximum

54,00

Range

32,00

Interquartile Range

11,00

Skewness

,826

,501

Kurtosis

,105

,972

36,3810

2,14640

Mean
95% Confidence Interval for

Lower Bound

31,9036

Mean

Upper Bound

40,8583

5% Trimmed Mean

35,9233

Median

35,0000

Variance

96,748

Universitas Sumatera Utara

65

Std. Deviation

Tenofovir

9,83604

Minimum

21,00

Maximum

60,00

Range

39,00

Interquartile Range

13,50

Skewness

,893

,501

Kurtosis

,410

,972

33,8571

2,23744

Mean
95% Confidence Interval for

Lower Bound

29,1899

Mean

Upper Bound

38,5244

5% Trimmed Mean

33,1164

Median

30,0000

Variance

105,129

Std. Deviation

10,25322

Minimum

21,00

Maximum

60,00

Range

39,00

Interquartile Range

IMT

Naive

8,00

Skewness

1,534

,501

Kurtosis

1,959

,972

20,7190

,65526

Mean
95% Confidence Interval for

Lower Bound

19,3522

Mean

Upper Bound

22,0859

5% Trimmed Mean

20,6254

Median

21,2000

Variance

9,017

Std. Deviation

3,00277

Minimum

15,90

Maximum

27,30

Range

11,40

Interquartile Range

3,90

Skewness

,165

,501

-,037

,972

23,2000

,75763

Kurtosis
Zidovudine

Mean
95% Confidence Interval for

Lower Bound

21,6196

Mean

Upper Bound

24,7804

5% Trimmed Mean

23,0767

Median

22,8000

Universitas Sumatera Utara

66

Variance

12,054

Std. Deviation

Tenofovir

3,47189

Minimum

17,60

Maximum

31,00

Range

13,40

Interquartile Range

3,90

Skewness

,775

,501

Kurtosis

,830

,972

22,0333

,73515

Mean
95% Confidence Interval for

Lower Bound

20,4998

Mean

Upper Bound

23,5668

5% Trimmed Mean

21,8471

Median

21,8000

Variance

11,349

Std. Deviation

CD4

Naive

3,36888

Minimum

17,10

Maximum

30,40

Range

13,30

Interquartile Range

3,65

Skewness

,962

,501

Kurtosis

,897

,972

152,8571

30,47077

Mean
95% Confidence Interval for

Lower Bound

89,2962

Mean

Upper Bound

216,4181

5% Trimmed Mean

143,7090

Median

136,0000

Variance

19497,829

Std. Deviation

139,63463

Minimum

7,00

Maximum

467,00

Range

460,00

Interquartile Range

239,50

Skewness
Kurtosis
Zidovudine

Mean

,772

,501

-,427

,972

333,7143

31,44369

95% Confidence Interval for

Lower Bound

268,1239

Mean

Upper Bound

399,3047

5% Trimmed Mean

330,6085

Universitas Sumatera Utara

67

Median

316,0000

Variance

20762,814

Std. Deviation

144,09308

Minimum

92,00

Maximum

633,00

Range

541,00

Interquartile Range

222,00

Skewness

,243

,501

-,360

,972

306,7143

44,09493

Kurtosis
Tenofovir

Mean
95% Confidence Interval for

Lower Bound

214,7339

Mean

Upper Bound

398,6947

5% Trimmed Mean

291,8122

Median

260,0000

Variance

40831,614

Std. Deviation

202,06834

Minimum

84,00

Maximum

799,00

Range

715,00

Interquartile Range

272,50

Skewness

1,225

,501

Kurtosis

1,100

,972

Tests of Normality Usia, IMT, CD4
Kolmogorov-Smirnova
rejimen
usia

IMT

CD4

Statistic

Naive

df

,138

Shapiro-Wilk

Sig.

Statistic

df

Sig.

21

,200*

,923

21

,098

*

Zidovudine

,148

21

,200

,926

21

,115

Tenofovir

,227

21

,006

,830

21

,002

Naive

,164

21

,144

,958

21

,486

*

Zidovudine

,112

21

,200

,939

21

,206

Tenofovir

,171

21

,113

,930

21

,139

Naive

,165

21

,138

,892

21

,024

*

Zidovudine

,111

21

,200

,974

21

,810

Tenofovir

,158

21

,185

,876

21

,012

*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction

Universitas Sumatera Utara

68

Profil Lipid berdasarkan rejimen pengobatan
Descriptives kadar profil lipid
rejimen
kolest

Naive

Statistic
Mean

145,2857

95% Confidence Interval for

Lower Bound

131,9491

Mean

Upper Bound

158,6223

5% Trimmed Mean

142,7354

Median

138,0000

Variance

29,29871

Minimum

99,00

Maximum

239,00

Range

140,00

Interquartile Range

29,50

Skewness

1,685

,501

Kurtosis

4,431

,972

189,7143

5,38169

Mean
95% Confidence Interval for

Lower Bound

178,4883

Mean

Upper Bound

200,9403

5% Trimmed Mean

189,9048

Median

195,0000

Variance

608,214

Std. Deviation

Tenofovir

6,39350

858,414

Std. Deviation

Zidovudine

Std. Error

24,66200

Minimum

144,00

Maximum

232,00

Range

88,00

Interquartile Range

39,00

Skewness

-,031

,501

Kurtosis

-,856

,972

200,8095

11,31342

Mean
95% Confidence Interval for

Lower Bound

177,2101

Mean

Upper Bound

224,4089

5% Trimmed Mean

201,7116

Median

217,0000

Variance

2687,862

Std. Deviation

51,84459

Universitas Sumatera Utara

69

trigliserid

Naive

Zidovudine

Minimum

105,00

Maximum

281,00

Range

176,00

Interquartile Range

82,50

Skewness

-,394

,501

Kurtosis

-,832

,972

123,4286

8,44691

Mean
95% Confidence Interval for

Lower Bound

105,8086

Mean

Upper Bound

141,0485

5% Trimmed Mean

123,2937

Median

129,0000

Variance

1498,357

Std. Deviation

38,70862

Minimum

53,00

Maximum

197,00

Range

144,00

Interquartile Range

56,00

Skewness

-,151

,501

Kurtosis

-,455

,972

123,0000

11,97299

Mean
95% Confidence Interval for

Lower Bound

98,0248

Mean

Upper Bound

147,9752

5% Trimmed Mean

121,0873

Median

113,0000

Variance

3010,400

Std. Deviation

54,86711

Minimum

46,00

Maximum

235,00

Range

189,00

Interquartile Range

84,50

Skewness
Kurtosis
Tenofovir

Mean

,620

,501

-,410

,972

153,3333

20,41957

95% Confidence Interval for

Lower Bound

110,7389

Mean

Upper Bound

195,9278

5% Trimmed Mean

148,9815

Median

129,0000

Variance

8756,133

Std. Deviation

93,57421

Universitas Sumatera Utara

70

Minimum

30,00

Maximum

355,00

Range

325,00

Interquartile Range

117,50

Skewness
Kurtosis
HDL

Naive

Mean

,487

,972

30,9524

2,08335

Lower Bound

26,6066

Mean

Upper Bound

35,2982

5% Trimmed Mean

30,8042

Median

34,0000
91,148

Std. Deviation

9,54713

Minimum

12,00

Maximum

53,00

Range

41,00

Interquartile Range

13,00

Skewness

-,142

,501

,556

,972

49,6667

2,75451

Kurtosis
Mean
95% Confidence Interval for

Lower Bound

43,9209

Mean

Upper Bound

55,4125

5% Trimmed Mean

49,6190

Median

47,0000

Variance

159,333

Std. Deviation

12,62273

Minimum

29,00

Maximum

71,00

Range

42,00

Interquartile Range

23,00

Skewness
Kurtosis
Tenofovir

,501

95% Confidence Interval for

Variance

Zidovudine

1,076

Mean

,193

,501

-,979

,972

44,9524

2,97408

95% Confidence Interval for

Lower Bound

38,7486

Mean

Upper Bound

51,1562

5% Trimmed Mean

44,5185

Median

42,0000

Variance

185,748

Std. Deviation

13,62893

Universitas Sumatera Utara

71

Minimum

25,00

Maximum

73,00

Range

48,00

Interquartile Range

17,50

Skewness
Kurtosis
LDL

Naive

Mean

-,398

,972

91,5714

5,68103

Lower Bound

79,7210

Mean

Upper Bound

103,4219

5% Trimmed Mean

89,8413

Median

88,0000

Variance

677,757
26,03377

Minimum

55,00

Maximum

160,00

Range

105,00

Interquartile Range

23,00

Skewness

1,121

,501

Kurtosis

1,429

,972

123,0000

6,36134

Mean
95% Confidence Interval for

Lower Bound

109,7305

Mean

Upper Bound

136,2695

5% Trimmed Mean

121,1190

Median

122,0000

Variance

849,800

Std. Deviation

Tenofovir

,501

95% Confidence Interval for

Std. Deviation

Zidovudine

,504

29,15133

Minimum

71,00

Maximum

211,00

Range

140,00

Interquartile Range

36,50

Skewness

1,094

,501

Kurtosis

3,165

,972

124,5238

8,15844

Mean
95% Confidence Interval for

Lower Bound

107,5056

Mean

Upper Bound

141,5420

5% Trimmed Mean

125,5794

Median

130,0000

Universitas Sumatera Utara

72

Variance

1397,762

Std. Deviation

37,38665

Minimum

46,00

Maximum

183,00

Range

137,00

Interquartile Range

58,50

Skewness

-,371

,501

Kurtosis

-,571

,972

Tests of Normality
Kolmogorov-Smirnova
rejimen
kolest

trigliserid

HDL

LDL

Naive

Statistic
,150

df

Shapiro-Wilk

Sig.

Statistic

df

Sig.

21

,200*

,869

21

,009

*

Zidovudine

,109

21

,200

,970

21

,733

Tenofovir

,146

21

,200*

,955

21

,417

21

*

,981

21

,935

*

Naive

,098

,200

Zidovudine

,135

21

,200

,941

21

,229

Tenofovir

,203

21

,024

,880

21

,015

Naive

,163

21

,150

,948

21

,313

*

Zidovudine

,115

21

,200

,953

21

,387

Tenofovir

,157

21

,190

,946

21

,284

Naive

,168

21

,124

,908

21

,050

21

*

,918

21

,078

*

,964

21

,591

Zidovudine
Tenofovir

,140
,135

21

,200
,200

Universitas Sumatera Utara

73

Uji Kruskal Wallis

Universitas Sumatera Utara

74

UJI ANOVA
Sum of Squares
IMT

Between Groups

df
2

32,353

Within Groups

648,399

60

10,807

Total

713,104

62

335648571428,5

Total

Sig.

2,994

,058

13,683

,000

7,451

,001

60 5594142857,143

71
361280857142,8

62

57

LDL

F

64,705

Within Groups

HDL

Mean Square

Between Groups

3979,143

2

1989,571

Within Groups

8724,571

60

145,410

Total

12703,714

62

Between Groups

14531,556

2

7265,778

Within Groups

58506,381

60

975,106

Total

73037,937

62

Post Hoc Tests
Multiple Comparisons
Bonferroni
Dependent

95% Confidence Interval

Mean Difference (I-

Variable

(I) rejimen

(J) rejimen

Lower Bound

Upper Bound

IMT

Naive

Zidovudine

-2,48095

1,01450

,052

-4,9796

,0177

Tenofovir

-1,31429

1,01450

,600

-3,8129

1,1844

2,48095

1,01450

,052

-,0177

4,9796

Tenofovir

1,16667

1,01450

,764

-1,3320

3,6653

Naive

1,31429

1,01450

,600

-1,1844

3,8129

-1,16667

1,01450

,764

-3,6653

1,3320

-48000,00000

23081,93038

,126

-104849,7139

8849,7139

34142,85714

23081,93038

,433

-22706,8568

90992,5710

-13857,14286

23081,93038

1,000

-70706,8568

42992,5710

Naive

48000,00000

23081,93038

,126

-8849,7139

104849,7139

Zidovudine

13857,14286

23081,93038

1,000

-42992,5710

70706,8568

Zidovudine

-18,71429

*

3,72136

,000

-27,8798

-9,5487

-14,00000

*

3,72136

,001

-23,1655

-4,8345

18,71429

*

3,72136

,000

9,5487

27,8798

4,71429

3,72136

,630

-4,4513

13,8798

Zidovudine Naive

Tenofovir

Zidovudine
Tenofovir
Zidovudine Naive
Tenofovir
Tenofovir

HDL

Naive

Tenofovir
Zidovudine Naive
Tenofovir

J)

Std. Error

Sig.

Universitas Sumatera Utara

75

Tenofovir

LDL

Naive

*

3,72136

,001

4,8345

23,1655

Zidovudine

-4,71429

3,72136

,630

-13,8798

4,4513

Zidovudine

-31,42857

*

9,63677

,005

-55,1635

-7,6937

-32,95238

*

9,63677

,003

-56,6873

-9,2175

31,42857

*

9,63677

,005

7,6937

55,1635

-1,52381

9,63677

1,000

-25,2587

22,2111

*

9,63677

,003

9,2175

56,6873

1,52381

9,63677

1,000

-22,2111

25,2587

Naive

14,00000

Tenofovir
Zidovudine Naive
Tenofovir
Tenofovir

Naive

32,95238

Zidovudine
*. The mean difference is significant at the 0.05 level.

Proporsi Kadar Lipid berdasarkan kriteria dislipidemia
Kolesterol total
Cumulative
Frequency
Valid

Percent

Valid Percent

Percent

>=200 mg/dl

19

30,2

30,2

30,2

< 200 mg/dl

44

69,8

69,8

100,0

Total

63

100,0

100,0

Trigliserida
Cumulative
Frequency
Valid

Percent

Valid Percent

Percent

>= 150 mg/dl

18

28,6

28,6

28,6

= 40 mg/dl

32

50,8

50,8

100,0

Total

63

100,0

100,0

LDL
Cumulative
Frequency
Valid

Percent

Valid Percent

Percent

>= 130 mg/dl

23

36,5

36,5

36,5

< 130 mg/dl

40

63,5

63,5

100,0

Total

63

100,0

100,0

Universitas Sumatera Utara

76

Dislipidemia
Cumulative
Frequency
Valid

Percent

Valid Percent

Percent

ya

50

79,4

79,4

79,4

tidak

13

20,6

20,6

100,0

Total

63

100,0

100,0

jk * Dislipidemia Crosstabulation
Dislipidemia
ya
jk

Laki-laki

Count

8

37

29,4

7,6

37,0

% within jk

78,4%

21,6%

100,0%

% within Dislipidemia

58,0%

61,5%

58,7%

21

5

26

20,6

5,4

26,0

% within jk

80,8%

19,2%

100,0%

% within Dislipidemia

42,0%

38,5%

41,3%

50

13

63

50,0

13,0

63,0

79,4%

20,6%

100,0%

100,0%

100,0%

100,0%

Count
Expected Count

Total

Total

29

Expected Count

Perempuan

tidak

Count
Expected Count
% within jk
% within Dislipidemia

Chi-Square Tests

Value

df

Asymp. Sig. (2-

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

sided)

a

1

,817

Continuity Correction

,000

1

1,000

Likelihood Ratio

,054

1

,817

Pearson Chi-Square

,053
b

Fisher's Exact Test
Linear-by-Linear Association
N of Valid Cases

1,000
,052

1

,819

63

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,37.
b. Computed only for a 2x2 table

Universitas Sumatera Utara

,538

77

Risk Estimate
95% Confidence Interval
Value
Odds Ratio for jk (Laki-laki /

,247

3,014

,970

,754

1,249

1,124

,414

3,051

For cohort Dislipidemia = ya

tidak

Upper

,863

Perempuan)

For cohort Dislipidemia =

Lower

N of Valid Cases

63

Descriptives
Dislipidemia
usia

ya

Statistic

Mean

36,2400

95% Confidence Interval for

Lower Bound

33,4539

Mean

Upper Bound

39,0261

5% Trimmed Mean

35,6556

Median

33,0000

Variance

1,38639

96,104

Std. Deviation

9,80329

Minimum

22,00

Maximum

60,00

Range

38,00

Interquartile Range

13,25

Skewness

1,017

,337

,178

,662

31,0000

1,87767

Kurtosis
tidak

Std. Error

Mean
95% Confidence Interval for

Lower Bound

26,9089

Mean

Upper Bound

35,0911

5% Trimmed Mean

30,8889

Median

29,0000

Variance
Std. Deviation

45,833
6,77003

Minimum

21,00

Maximum

43,00

Range

22,00

Interquartile Range

8,50

Universitas Sumatera Utara

78

Skewness
Kurtosis
IMT

ya

Mean

1,191

21,8640

,50907

20,8410

Mean

Upper Bound

22,8870

5% Trimmed Mean

21,6867

Median

21,6000
12,957
3,59965

Minimum

15,90

Maximum

31,00

Range

15,10

Interquartile Range

4,02

Skewness

,765

,337

Kurtosis

,638

,662

22,4462

,69195

Mean
95% Confidence Interval for

Lower Bound

20,9385

Mean

Upper Bound

23,9538

5% Trimmed Mean

22,4457

Median

22,0000

Variance

6,224

Std. Deviation

ya

-,400

Lower Bound

Std. Deviation

CD4

,616

95% Confidence Interval for

Variance

tidak

,324

2,49487

Minimum

17,60

Maximum

27,30

Range

9,70

Interquartile Range

3,30

Skewness

,015

,616

Kurtosis

,458

1,191

252,2400

27,10800

Mean
95% Confidence Interval for

Lower Bound

197,7644

Mean

Upper Bound

306,7156

5% Trimmed Mean

237,9556

Median

207,5000

Variance

36742,186

Std. Deviation

191,68251

Minimum

7,00

Maximum

799,00

Range

792,00

Universitas Sumatera Utara

79

Interquartile Range

tidak

269,00

Skewness

,958

,337

Kurtosis

,733

,662

311,3077

34,46038

Mean
95% Confidence Interval for

Lower Bound

236,2250

Mean

Upper Bound

386,3904

5% Trimmed Mean

312,8974

Median

316,0000

Variance

15437,731

Std. Deviation

124,24867

Minimum

111,00

Maximum

483,00

Range

372,00

Interquartile Range

182,00

Skewness

-,317

,616

Kurtosis

-,901

1,191

Tests of Normality
Kolmogorov-Smirnova
Dislipidemia
usia

IMT

CD4

ya

Statistic

df

,170

Shapiro-Wilk

Sig.

Statistic

df

Sig.

50

,001

,893

50

,000

*

tidak

,175

13

,200

,933

13

,368

ya

,125

50

,049

,944

50

,020

*

tidak

,109

13

,200

,988

13

,999

ya

,111

50

,167

,927

50

,004

tidak

,177

13

,200*

,938

13

,430

*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction

Universitas Sumatera Utara

80

Nonparametric Tests

Rejimen Pengobatan * Dislipidemia Crosstabulation
Dislipidemia
ya
Rejimen Pengobatan

Naive

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

Zidovudine

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

Tenofovir

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

tidak

Total

20

1

21

16,7

4,3

21,0

95,2%

4,8%

100,0%

40,0%

7,7%

33,3%

12

9

21

16,7

4,3

21,0

57,1%

42,9%

100,0%

24,0%

69,2%

33,3%

18

3

21

16,7

4,3

21,0

85,7%

14,3%

100,0%

36,0%

23,1%

33,3%

Universitas Sumatera Utara

81

Total

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

50

13

63

50,0

13,0

63,0

79,4%

20,6%

100,0%

100,0%

100,0%

100,0%

Chi-Square Tests
Asymp. Sig. (2Value
Pearson Chi-Square
Likelihood Ratio

sided)

10,080a

2

,006

10,196

2

,006

,572

1

,449

Linear-by-Linear Association
N of Valid Cases
a.

df

63

3 cells (50,0%) have expected count less than 5. The minimum
expected count is 4,33.

Rejimen Pengobatan * Dislipidemia Crosstabulation
Dislipidemia
ya
Rejimen Pengobatan

Naive

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

Zidovudine

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

Total

Count
Expected Count
% within Rejimen
Pengobatan
% within Dislipidemia

tidak

Total

20

1

21

16,0

5,0

21,0

95,2%

4,8%

100,0%

62,5%

10,0%

50,0%

12

9

21

16,0

5,0

21,0

57,1%

42,9%

100,0%

37,5%

90,0%

50,0%

32

10

42

32,0

10,0

42,0

76,2%

23,8%

100,0%

100,0%

100,0%

100,0%

Universitas Sumatera Utara

82

Chi-Square Tests

Value

Asymp. Sig. (2-

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

sided)

df

8,400a

1

,004

Continuity Correction

6,431

1

,011

Likelihood Ratio

9,383

1

,002

Pearson Chi-Square
b

Fisher's Exact Test

,009

Linear-by-Linear Association

8,200

N of Valid Cases

1

,004

,004

42

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,00.
b. Computed only for a 2x2 table

Risk Estimate
95% Confidence Interval
Value

Lower

Upper

Odds Ratio for Rejimen
Pengobatan (Naive /

15,000

1,685

133,551

1,667

1,137

2,443

,111

,015

,801

Zidovudine)
For cohort Dislipidemia = ya
For cohort Dislipidemia =
tidak
N of Valid Cases

42

Rejimen Pengobatan * Dislipidemia Crosstabulation
Dislipidemia
ya
Rejimen Pengobatan

Naive

Count
% within Rejimen
Pengobatan
% within Dislipidemia

Tenofovir

Count
% within Rejimen
Pengobatan
% within Dislipidemia

Total

Count
% within Rejimen
Pengobatan
% within Dislipidemia

tidak

Total

20

1

21

95,2%

4,8%

100,0%

52,6%

25,0%

50,0%

18

3

21

85,7%

14,3%

100,0%

47,4%

75,0%

50,0%

38

4

42

90,5%

9,5%

100,0%

100,0%

100,0%

100,0%

Universitas Sumatera Utara

83

Chi-Square Tests

Value
Pearson Chi-Square

df

Continuity Correction
Likelihood Ratio

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

sided)

a

1

,293

,276

1

,599

1,152

1

,283

1,105
b

Asymp. Sig. (2-

Fisher's Exact Test

,606

Linear-by-Linear Association

1,079

N of Valid Cases

1

,299

42

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,00.
b. Computed only for a 2x2 table

Risk Estimate
95% Confidence Interval
Value

Lower

Upper

Odds Ratio for Rejimen
Pengobatan (Naive /

3,333

,318

34,989

1,111

,911

1,356

,333

,038

2,951

Tenofovir)
For cohort Dislipidemia = ya
For cohort Dislipidemia =
tidak
N of Valid Cases

42

Logistic Regression
Categorical Variables Codings
Parameter coding
Frequency
Rejimen Pengobatan

(1)

(2)

Naive

21

,000

,000

Zidovudine

21

1,000

,000

Tenofovir

21

,000

1,000

Universitas Sumatera Utara

,303

84

Block 0: Beginning Block
Classification Tablea,b
Predicted
Dislipidemia
Observed
Step 0

tidak

Dislipidemia

Percentage

ya

Correct

tidak

0

13

,0

ya

0

50

100,0

Overall Percentage

79,4

a. Constant is included in the model.
b. The cut value is ,500

Variables in the Equation
B
Step 0

Constant

S.E.

1,347

Wald

,311

df

Sig.

18,722

1

,000

Exp(B)
3,846

Variables not in the Equation
Score
Step 0

Variables

df

Sig.

usia

3,220

1

,073

CD

1,122

1

,290

10,080

2

,006

rejimen(1)

9,498

1

,002

rejimen(2)

,775

1

,379

14,267

4

,006

rejimen

Overall Statistics

Block 1: Method = Enter
Omnibus Tests of Model Coefficients
Chi-square
Step 1

df

Sig.

Step

16,049

4

,003

Block

16,049

4

,003

Model

16,049

4

,003

Model Summary

Step
1

-2 Log likelihood
48,095a

Cox & Snell R

Nagelkerke R

Square

Square
,225

,352

a. Estimation terminated at iteration number 6 because
parameter estimates changed by less than ,001.

Universitas Sumatera Utara

85

Classification Tablea
Predicted
Dislipidemia
Observed
Step 1

Dislipidemia

tidak

Percentage

ya

Correct

tidak

5

8

38,5

ya

5

45

90,0

Overall Percentage

79,4

a. The cut value is ,500
Variables in the Equation
95% C.I.for EXP(B)
B
a

Step 1

S.E.

Wald

df

Sig.

Exp(B)

Lower

Upper

usia

,112

,055

4,124

1

,042

1,119

1,004

1,246

CD

,000

,002

,039

1

,844

1,000

,995

1,004

8,811

2

,012

rejimen
rejimen(1)

-2,956

1,210

5,966

1

,015

,052

,005

,558

rejimen(2)

-,975

1,261

,598

1

,439

,377

,032

4,463

Constant

-,558

1,999

,078

1

,780

,573

a. Variable(s) entered on step 1: usia, CD, rejimen.

Logistic Regression
Categorical Variables Codings
Parameter coding
Frequency
Rejimen Pengobatan

(1)

(2)

Naive

21

,000

,000

Zidovudine

21

1,000

,000

Tenofovir

21

,000

1,000

Block 0: Beginning Block
Classification Tablea,b
Predicted
Dislipidemia
Observed
Step 0

Dislipidemia

tidak

Percentage

ya

Correct

tidak

0

13

,0

ya

0

50

100,0

Overall Percentage

79,4

a. Constant is included in the model.
b. The cut value is ,500

Universitas Sumatera Utara

86

Variables in the Equation
B
Step 0

Constant

S.E.

1,347

Wald

,311

df

Sig.

18,722

1

,000

Exp(B)
3,846

Variables not in the Equation
Score
Step 0

Variables

usia

df

Sig.

3,220

1

,073

10,080

2

,006

rejimen(1)

9,498

1

,002

rejimen(2)

,775

1

,379

14,262

3

,003

rejimen

Overall Statistics

Block 1: Method = Enter
Omnibus Tests of Model Coefficients
Chi-square
Step 1

df

Sig.

Step

16,011

3

,001

Block

16,011

3

,001

Model

16,011

3

,001

Model Summary

Step
1

Cox & Snell R

Nagelkerke R

Square

Square

-2 Log likelihood
a

48,133

,224

,351

a. Estimation terminated at iteration number 6 because
parameter estimates changed by less than ,001.

Classification Tablea
Predicted
Dislipidemia
Observed
Step 1

Dislipidemia

tidak

Percentage

ya

Correct

tidak

5

8

38,5

ya

5

45

90,0

Overall Percentage

79,4

a. The cut value is ,500

Universitas Sumatera Utara

87

Variables in the Equation
95% C.I.for EXP(B)
B
Step 1a

usia

,112

S.E.
,056

rejimen

Wald

df

Sig.

4,053

1

,044

9,421

2

,009

Exp(B)

Lower

Upper

1,118

1,003

1,247

rejimen(1)

-3,022

1,164

6,745

1

,009

,049

,005

,476

rejimen(2)

-1,035

1,221

,718

1

,397

,355

,032

3,892

Constant

-,634

1,978

,103

1

,749

,531

a. Variable(s) entered on step 1: usia, rejimen.

Universitas Sumatera Utara

88

Lampiran 7
MASTER TABEL

Profil Lipid
NO

Nama

Reji
men
ARV

Umur
(Thn)

Sex

Pen
didi
kan

Pek
erja
an

Ala
mat

Fak
tor
Risi
ko

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Sh
SMS
ES
MS
AW
SAN
JS
OT
AS
HS
Bi
SS
EPS
Kp
SG
EPD
RA
JJS
NG
MLT
AN
Si
PS
DHA
ER
LS
Bu
SSS
MK
RM
HS
RKM
KH
LM
HHDM
AB
AS
BST
Ar
NS
MT
MF
He
DIN
Id

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3

28
44
36
54
33
29
28
33
36
39
39
33
35
51
38
30
22
28
28
49
27
51
43
42
21
31
35
35
29
54
37
27
43
38
32
28
29
60
28
29
41
31
32
36
26

2
2
1
1
1
2
1
2
1
1
2
1
1
2
2
1
2
1
2
2
1
2
1
2
1
1
1
2
1
1
1
1
2
2
1
1
1
2
2
2
1
2
1
1
1

3
5
3
3
5
5
3
2
4
2
3
3
3
1
2
3
3
3
4
2
3
1
2
4
3
5
1
3
5
1
5
5
3
1
5
1
3
3
3
5
3
3
5
5
5

2
5
1
1
1
5
5
2
6
1
2
4
1
2
3
1
3
6
2
4
1
3
7
1
8
6
1
1
3
1
1
1
5
2
6
6
1
2
3
6
1
3
6
1
5

3
5
5
9
7
7
7
1
3
3
1
9
1
3
5
5
4
3
3
4
10
2
3
3
3
3
3
1
3
11
3
6
11
9
3
1
3
5
3
9
3
5
3
8
3

1
1
1
1
5
1
1
1
1
1
4
1
1
1
1
1
1
6
1
5
1
1
1
1
2
1
2
6
1
1
1
1
1
1
1
1
3
1
1
1
1
1
1
1
2

IMT

CD4
(Cell/
Ul)

18.6
20.8
15.9
18.2
21.9
20.8
21.3
23
22.4
25.6
21.2
16
19.1
20.7
23.8
16.9
22.2
21.2
27.3
21.6
16.6
21.8
24.3
20
17.6
22.8
22
26.1
23.5
30.9
18.1
22
24.9
21.6
23.4
21.3
20.8
26.2
19.9
24
25
31
22.9
27
20.8

92
170
13
15
467
279
385
34
150
25
136
85
43
244
301
7
344
16
235
150
19
181
112
387
400
396
479
266
199
633
301
92
294
316
480
382
441
578
289
387
197
198
332
94
225

Koleste
rol total
(mg/dL)

Triglis
erida
(mg/d
L)

HDL
(mg/
dL)

LDL
(mg/d
L)

120
143
127
128
160
135
154
133
123
138
165
150
99
186
135
174
239
129
151
122
140
195
179
215
153
159
196
223
232
197
171
176
219
171
172
195
202
223
188
169
144
205
231
264
222

162
107
163
132
135
56
197
156
83
149
73
143
126
136
111
179
88
53
109
105
129
128
113
182
84
95
109
235
98
117
148
181
205
60
221
122
46
134
76
48
73
108
124
346
129

22
15
12
34
29
36
25
38
22
29
38
34
17
37
35
35
53
32
41
34
32
29
45
35
43
54
42
35
70
47
62
35
54
71
34
61
63
52
47
45
51
68
42
35
50

55
88
76
87
105
94
101
62
80
81
139
97
64
131
90
93
160
78
99
61
82
142
114
144
93
100
122
140
211
140
149
107
132
88
103
109
114
143
125
106
71
130
144
153
128

Universitas Sumatera Utara

89

Profil Lipid
NO

Nama

Reji
men
ARV

Umur
(Thn)

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

Fi
TH
DSN
JL
MAR
JS
HLPN
TF
MAH
RH
HLT
JDB
Jr
TT
DMM
Zu
LE
PS

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

28
32
30
24
25
33
47
28
30
36
34
43
21
58
29
30
29
60

Sex

2
2
1
1
2
1
1
1
2
2
1
1
1
2
1
1
2
1

Pen
didi
kan

Pek
erja
an

Ala
mat

Fak
tor
Risi
ko

3
3
5
5
3
2
3
3
3
3
5
5
3
1
3
3
3
5

3
3
6
6
3
1
1
1
6
1
1
1
2
4
1
1
6
2

3
3
3
3
3
3
3
3
3
4
3
3
3
5
3
3
3
1

1
1
1
2
1
1
1
2
1
1
1
2
2
1
5
1
1
1

IMT

CD4
(Cell/
Ul)

19
21.8
22
30.4
19.9
17.5
22
20.4
19.5
21.9
20.8
22.7
23.8
17.1
24.6
18.7
21.6
28.3

207
111
208
200
360
287
287
483
129
464
113
761
260
160
507
84
799
370

Koleste
rol total
(mg/dL)

Triglis
erida
(mg/d
L)

HDL
(mg/
dL)

LDL
(mg/d
L)

184
109
195
263
231
219
196
156
257
105
130
146
157
176
242
236
217
281

140
105
79
152
76
200
215
68
156
30
111
214
39
122
355
131
100
328

37
47
41
67
73
45
27
51
42
25
25
64
56
34
41
64
41
37

108
81
144
172
143
134
126
85
179
46
72
106
77
101
130
153
150
183

KETERANGAN MASTER TABEL
Rejimen ARV
(1) Naïve
(2) Zidovudine
(3) Tenofovir
Jenis Kelamin
(1) Laki-laki
(2) Perempuan
Pendidikan
(1) SD
(2) SMP
(3) SMA
(4) Akademi
(5) Sarjana S1
Pekerjaan
(1) Wiraswasta
(2) Tidak bekerja
(3) Ibu Rumah Tangga
(4) Petani
(5) PNS
(6) Karyawan swasta
(7) Supir
(8) Mahasiswa

Alamat
(1) Tanah Karo
(2) Binjai
(3) Medan
(4) Sibolga
(5) Deli Serdang
(6) Nias
(7) Aceh
(8) P. Siantar
(9) Simalungun
(10) Tobasa
(11) Dairi
Faktor Risiko
(1) Heteroseksual
(2) Homoseksual
(3) Biseksual
(4) Transfusi
(5) IDU
(6) Heteroseksual, Tatto

Universitas Sumatera Utara